Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT
- 1 May 2018
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 12 (3) , 277-287
Abstract
Plasma microRNA (miRNA) levels may be altered during pathological processes; therefore, they may potentially serve as biomarkers for the diagnosis and prognosis of human diseases. This study aimed to explore whether plasma miRNAs may serve as new biomarkers for liver injury among chronic hepatitis B (CHB) patients with normal or nearly normal alanine aminotransferase (ALT) levels.Keywords
Funding Information
- National Science and Technology Major Project (2012ZX10002004-001)
- Science Fund for Creative Research Groups of the National Natural Science Foundation of China (81121002)
This publication has 31 references indexed in Scilit:
- Didymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor ProteinCellular Physiology and Biochemistry, 2016
- Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver diseaseGenetics and Molecular Research, 2014
- Circulating MicroRNAsCirculation Research, 2012
- Serum microRNA‐122 levels in different groups of patients with chronic hepatitis B virus infectionJournal of Viral Hepatitis, 2011
- Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver DiseasePLOS ONE, 2011
- The widespread regulation of microRNA biogenesis, function and decayNature Reviews Genetics, 2010
- MicroRNA control of signal transductionNature Reviews Molecular Cell Biology, 2010
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Prediction of both conserved and nonconserved microRNA targets in animalsBioinformatics, 2007
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995